

Sleep Services Billing Guide 2025

remedē° System

Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea

O



The remede® System Sleep Services Billing Guide

This guide contains coding and reimbursement information for sleep procedures associated with the **rem**edē System to treat moderate to severe central sleep apnea.

At ZOLL, we're committed to partnering with you throughout every step of the coverage, coding, and reimbursement processes—delivering the hands-on assistance you need to enjoy a seamless experience.

At any time, reach out to the remedē Reimbursement team at **1-952-540-4470** or <u>reimbursement@remede.zoll.com</u> for support with:

- Prior authorizations & appeals (including peer-to-peers)
- · Claim appeals
- Billing, coding or coverage questions
- Any additional information

We look forward to collaborating with you to remove access barriers and ensure that **rem**edē's cost and reimbursements are aligned—so that more patients can benefit from this life-changing therapy.

This guide and all supporting documents are available for download at remede.zoll.com/reimbursement.

Disclaimer: The information provided in this guide is general reimbursement information only; it is not legal advice, nor is it advice about how to code, complete or submit any claim for payment, nor is it intended to increase or maximize reimbursement by any third-party payer. All coding and reimbursement information is subject to change without notice.

The content provided by the Center for Medicare and Medicaid Services is updated frequently. It is the responsibility of the health services provider to confirm the appropriate coding required by their local Medicare carriers, fiscal intermediaries, and commercial payers.

CONTENTS

TRANSVENOUS PHRENIC NERVE STIMULATION FOR CENTRAL SLEEP APNEA 4
Therapy Overview
Device and Implant Procedure4
Programming & Analysis4
COVERAGE
FDA Approval
Medicare Coverage5
Commercial Payer Coverage5
Sleep Studies
Denials and Appeals6
CODING
Diagnosis Codes
Qualifying Polysomnogram or Home Sleep Test7
Daytime Clinic Visits
Therapy Activation
9 Device Optimization & Ongoing Follow-up
Example Pathway and Coding9
BILLING AND PAYMENT9
Billing Considerations10
Physician Billing10
Physician CMS-1500 Programming Billing Example11

TRANSVENOUS PHRENIC NERVE STIMULATION FOR CENTRAL SLEEP APNEA

Therapy Overview

The **rem**edē[®] System is an implantable system that safely and effectively treats moderate to severe Central Sleep Apnea (CSA) in adult patients.¹ CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and has been shown to negatively impact quality of life and cardiovascular health.² The **rem**edē System is an implantable system that stimulates a nerve in the chest (the phrenic nerve) to send signals to the large muscle that controls breathing (the diaphragm).

In a clinical study, the **rem**edē System has been shown to significantly improve CSA patient outcomes:

- 96% reduction in Central Apnea Index³
- 95% of patients reported they would "elect to have the medical procedure again"⁴
- 78% of patients reported improved quality of life⁴
- Significant reduction in arousals and improvement in sleep architecture³

Device and Implant Procedure


The **rem**edē System is placed during a minimally invasive procedure. The system consists of a battery powered Implantable Pulse Generator (IPG) device placed under the skin in the upper chest area with one or two small thin wires (leads). One lead delivers the therapy to stimulate the phrenic nerve (stimulation lead). For select models, an optional sensing lead may be used for diagnostic purposes to sense breathing (sensing lead).

Programming & Analysis

There are three different types of programming sessions that occur for patients with the **rem**edē System.

The **Therapy Activation** session is the first programming session when the device stimulation is activated and often occurs 6 weeks after the implant procedure. During this visit, the device data is reviewed and initial device programming occurs. Patient education also occurs.

The **Device Optimization** session occurs 6 weeks after therapy initiation and/or every 6-12 weeks until therapy delivery is stable. During this visit, the device data is reviewed and programming changes are made, as needed, to optimize therapy response and patient comfort. A subjective assessment is completed with the patient. This visit is often 30-45 minutes and most patients will require at least one iteration of adjustment and customization of program settings.



When individualized programming has been optimized, **Chronic Follow-up** is recommended every 3-6 months. During these visits, the device data is reviewed and minor programming changes are made, as needed, to optimize therapy response and patient comfort. A subjective assessment is completed with the patient which will determine the timing for the next visit. This visit is often 15-20 minutes.

COVERAGE

FDA Approval

The **rem**edē[®] System received Premarket Approval (PMA) from the FDA on October 6, 2017. The FDA-approved indications for use are as follows:

Indications for use: The **rem**edē System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe CSA in adult patients.

Contraindications: The remedē System is contraindicated for patients with an active infection.

The Instructions for Use document provides further information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events. The FDA has posted 1) the Summary of Safety and Effectiveness Data (SSED), 2) the FDA Approval Letter, 3) the Implant System Directions for Use (Physician Labeling), and 4) the Patient Guide (Patient Labeling) on its website located at: https://www.fda.gov/medical-devices/recently-approved-devices/remeder-system-p160039

Medicare Coverage

Currently, there is no National Coverage Determination (NCD) related to the **rem**edē System. Check with your local Medicare Administrative Contractor (MAC) regarding any Local Coverage Determinations (LCDs) related to the **rem**edē System. Medicare may cover the **rem**edē System on a case-by-case basis, with evidence of medical necessity. While traditional Medicare does not require or allow prior authorization or prior approval for **rem**edē System procedures, Medicare Advantage plans may require prior authorization or may have specific Medicare Advantage coverage policies. Check with your billing and coding staff for any prior authorization requirements.

Commercial Payer Coverage

Unlike traditional Medicare, commercial payers may require prior authorization for the Polysomnogram (PSG) or programming services. Before scheduling a PSG, the specific insurance requirements for sleep studies should be verified and authorized if required.

Commercial insurance coverage policies vary and many require prior authorization for an elective procedure or services such as the **rem**edē System. We encourage Health Care Professionals (HCPs) to contact payer(s) directly with questions regarding coverage policies or guidelines for the **rem**edē System.

ZOLL offers the **rem**edē Patient Access Program which can assist in determining the availability of coverage for your patients and facilitating prior authorization support services.

Sleep Studies

It is also important to understand coverage regarding sleep studies for patients with the **rem**edē System. For Medicare beneficiaries, a single diagnostic and a single titration PSG are generally considered reasonable and necessary once per year.⁵ Any repeat diagnostic or titration studies will require justification of medical necessity for the additional services.

For commercial payers, sleep studies typically require prior authorization. A repeat sleep study may be considered medically necessary up to twice a year to assess the treatment response or as a result of persistent or new symptoms. However, commercial plans vary and it is important to confirm coverage with your plan administrator. Medicare Advantage plans may also have specific prior authorization requirements or coverage policies for sleep studies.

Coverage differences may also exist for split-night, full-night and home sleep studies.

Denials and Appeals

Payers may not write a coverage policy initially, instead opting to review on a case by case basis for medical necessity. In some cases, an appeal may be required to obtain a successful prior authorization or claim approval for the **rem**edē System. Most commercial health plans and Medicare Advantage plans have a method by which denials can be appealed through a process documented in the plan's Provider Manual. The **rem**edē Patient Access Program can assist you with this process. Contact the **rem**edē Reimbursement Hotline for additional information and resources to support your patient's appeal process.

CODING

This coding information is provided for general reimbursement information purposes only. It is not intended to provide advice about how to code, complete or submit any claim for payment, nor is it intended to increase or maximize reimbursement by any third-party payer. It is the responsibility of the health services provider to confirm the appropriate coding required by their local Medicare carriers, fiscal intermediaries, and commercial payers.

Diagnosis Codes

The **rem**edē System is used to treat moderate to severe CSA in adult patients.

ICD-10-CM Diagnosis Codes

Diagnosis coding for the *rem*edē System procedures may involve the following codes:

ICD-10-CM CODE ⁶	DESCRIPTOR
Insertion/Replace	ment/Removal
G47.31	Primary Central Sleep Apnea
G47.32	Central Sleep Apnea due to high altitude periodic breathing
G47.37	Central sleep apnea in conditions classified elsewhere

Diagnosis coding for routine interrogation and reprogramming may involve the following code:

ICD-10-CM CODE ⁶	DESCRIPTOR
Device Follow-up	Care
Z45.42	Encounter for adjustment and management of neuropacemaker; brain, peripheral nerve, spinal cord

Qualifying Polysomnogram or Home Sleep Test Coding

It is recommended that patients have a Polysomnogram (PSG) or Home Sleep Test (HST) documenting their CSA diagnosis within 24 months of consultation for the **rem**edē System. Keep in mind that certain sleep study technologies do not separately identify central and obstructive apneas, which is a critical metric in determining a patient's CSA diagnosis and eligibility for the **rem**edē System.

If medically necessary, the sleep physician may order a sleep test every 6-12 months to monitor the device and optimize therapy. CPT coding for the PSG/HST may involve the following codes:

					RVUS ⁷		MEDICAR	VERAGE E PHYSICIAN MENT ⁷	
CPT° CODE'	DESCRIPTION	OPPS	2025 AVERAGE MEDICARE OUTPATIENT PAYMENT ⁹	WORK	TOTAL - FACILITY	TOTAL - NON- FACILITY	TOTAL - FACILITY	TOTAL - NON- FACILITY	EXAMPLE ⁸
95810	Polysomnography; sleep staging with 4 or more additional parameters of sleep, attended by a technologist.	5724	\$1,017.39	2.50	3.47	18.81	\$112.24	\$608.44	In-lab PSG
95800	HST; Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time.	5721	\$156.46	0.85	1.15	3.85	\$37.20	\$124.53	WatchPAT
95801	HST; Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone)	5733	\$59.40	0.85	1.20	2.92	\$38.82	\$94.45	ResMed Apnea Link w/Oximetry
95806	HST; Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement)	5721	\$156.46	0.93	1.29	2.88	\$41.73	\$93.16	ResMed ApneaLink Air
G0398	Home sleep study test (HST) with type II portable monitor; unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/ heart rate, airflow, respiratory effort, and oxygen saturation			С	arrier Prio	ced			
G0399	Home sleep test (HST) with type III portable monitor; unattended; minimum of 4 channels: 2 respiratory movement/ airflow, 1 ECG/heart rate and 1 oxygen saturation			с	arrier Prio	ced			ResMed ApneaLink Air
G0400	Home sleep test (HST) with type IV portable monitor; unattended; minimum of 3 channels			c	arrier Prio	ced			WatchPAT, NightOwl

Daytime Clinic Visits Coding

After the **rem**edē System is implanted, it is common for the office visit to be billed along with the device activation or programming. In order to bill for the clinic visit, the Evaluation & Management (E/M) criteria must be separate and identifiable from the device programming activity and modifier-25 may be used with the E/M CPT code.

Sample of Clinic Visit CPT Codes

			RVUS ⁷	2025 AVERAGE MEDICARE PHYSICIAN PAYMENT ⁷		
CPT° CODE6	DESCRIPTION	WORK	TOTAL - FACILITY	TOTAL - NON-FACILITY	TOTAL - FACILITY	TOTAL - NON-FACILITY
99204	New patient office visit, Level 4	2.60	3.99	5.05	\$129.06	\$163.35
99205	New patient office visit, Level 5	3.50	5.43	6.67	\$175.64	\$215.75
99214	Established patient office visit, Level 4	1.92	2.90	3.87	\$93.80	\$125.18
99215	Established patient office visit, Level 5	2.80	4.29	5.43	\$138.77	\$175.64

Therapy Activation

The Therapy Activation session is the first programming session when the device stimulation is activated and often occurs 6 weeks after the implant procedure. This initial visit includes patient education and is an extended session of approximately 45 min-1 hour. Therapy activation requires patient participation to optimize therapy comfort and should not be done during a PSG, it is most often done as a clinic visit.

Therapy Activation				RVUS ⁷	2025 MEDICARE NATIONAL AVERAGE PAYMENT ⁷			
CPT° CODE	DESCRIPTION	OPPS APC	2025 MEDICARE OUTPATIENT PAYMENT [®]	WORK	TOTAL - FACILITY	TOTAL - NON- FACILITY	FACILITY	NON- FACILITY
93150	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming	5742	\$91.79	0.85	1.24	3.03	\$40.11	\$98.01

Device Optimization & Ongoing Follow-up

After therapy activation occurs, additional clinic visits may be needed every 6-12 weeks to optimize the therapy delivery and patient comfort. During these evaluations, the device data will be reviewed and any appropriate programming changes will occur. CPT code 93151 should be used when these changes occur during a clinic visit or CPT code 93152 if conducted during a PSG. CPT code 93153 should be used if only an interrogation occurs without any programming and it should not be combined with CPT code 93151 or 93152.

When therapy optimization has been attained, chronic follow-up should continue every 3-6 months based on individual patient needs. If medically necessary, these visits often include a patient assessment, device data review and minor programming changes.

Therapy Optimization and Follow-up				RVUS ⁷		2025 MEDICARE NATIONAL AVERAGE PAYMENT ⁷			
CPT° CODE	DESCRIPTION	OPPS APC	2025 MEDICARE OUTPATIENT PAYMENT ⁹	WORK	TOTAL - FACILITY	TOTAL - NON- FACILITY	WORK	FACILITY	NON- FACILITY
93151	Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system	5742	\$91.79	0.80	1.17	2.65	\$26.20	\$37.85	\$85.72
93152	Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography	5743	\$299.31	1.82	2.61	4.22	\$59.59	\$84.42	\$136.50
93153	Interrogation without programming of implanted phrenic nerve stimulator system	5742	\$91.79	0.43	0.64	1.58	\$14.08	\$20.70	\$51.11

Example Pathway and Coding

See below for an illustrative example of a **rem**edē patient pathway in Sleep Medicine and some of the commonly used CPT codes.

Engagements in	remedē journey	Sleep Medicine Coding
Implanting center	Sleep lab/clinic	
	New Patient Consult	99204/5 – Level 4/5 new patient office visit
	•	
	Evaluation	95810 – Attended PSG for adults (technical) • Interpretation fee (professional)
	Post-eval consult	99214/5 – Level 4/5 established patient office visit
L		
Implant	Activation	99214/5 – Level 4/5 established patient office visit 93150 – rem edē activation and programming
▶	Optimization	99214/5 – Level 4/5 established patient office visit 93151 – rem edē interrogation and programming
Repeat as needed	PSG/PG Confirmation	95810 – Attended PSG for adults (technical) • Interpretation fee (professional) 93152 – rem edē PSG with interrogation and programming
	Routine Follow-up	99214/5 – Level 4/5 established patient office visit 93151 – rem edē interrogation and programming

BILLING AND PAYMENT

Billing Considerations

It is important to include the prior authorization number for commercial payers when submitting the claim. It may also be beneficial to include the prior authorization number for the initial device implant procedure.

Payers have different billing requirements for programming and polysomnograms. Check with the payer at Prior Authorization.

CLAIM FORM ITEM	VALUES	NOTES
Item 21A	Diagnosis (primary)	Enter the primary ICD-10-CM diagnosis Codes (see page 7)
Item 23	Prior Authorization Number	Enter the payer's prior authorization number for patients with commercial and Medicare Advantage
Item 24D	Procedures, Services, or Supplies	Enter the CPT code for each procedure or service provided with one CPT code in each line

Physician CMS-1500 Programming Billing Example

See below for an illustrative example of a Physician Claim.

										PICA
. MEDICARE MEDICAID TRICARE (Medicare#) (Medicaid#) (ID#/DoD#)	CHAMPVA (Member ID	- HEALTH			R 1a. INSURED'S	I.D. NUMBE	ER		(For Program	in Item 1)
PATIENT'S NAME (Last Name, First Name, Middle Initial)		3. PATIENT'S BI		SEX	4. INSURED'S I	NAME (Last	Name, Firs	st Name,	Middle Initial)	
Patient Jane PATIENT'S ADDRESS (No., Street)		6. PATIENT REL	М		Patient Jan 7. INSURED'S		No Street			
776 American Way		Self Spo		Other	1776 Ameri)		
лту	STATE	8. RESERVED F		:	CITY	oan way				STATE
lometown	HS				Hometown					HS
IP CODE TELEPHONE (Include Area C	ode)				ZIP CODE		TEL	EPHON	E (Include Area)	Code)
2345 () OTHER INSURED'S NAME (Last Name, First Name, Middle In	nitial)	10. IS PATIENT'S	S CONDITION	RELATED TO:	12345 11. INSURED'S	POLICY GF	ROUP OR I	FECA N	JMBER	
OTHER INSURED'S POLICY OR GROUP NUMBER		a. EMPLOYMEN			a. INSURED'S MM	DATE OF BI	RTH YY		SEX	
. RESERVED FOR NUCC USE		b. AUTO ACCIDI	YES ENT?		b. OTHER CLA		inated by N	M		F
			YES	PLACE (State)		is (booly	, and by h			
RESERVED FOR NUCC USE		c. OTHER ACCII			c. INSURANCE	PLAN NAM	E OR PRO	IGRAM N	NAME	
INSURANCE PLAN NAME OR PROGRAM NAME		10d. CLAIM COE	YES		d. IS THERE AT				AN2	
INSURANCE PLAN NAME OF PROGRAM NAME		TUG. CLAIM COL	VES				te items 9, 9a, a	nd 9d.		
READ BACK OF FORM BEFORE CO 2. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE 1 au	MPLETING	& SIGNING THIS	FORM.	rmation necessary			RIZED PE	RSON'S	SIGNATURE I a	uthorize
to process this claim. I also request payment of government ben below.					services des	cribed below	w.	undersig	ned physician or	supplier for
SIGNED	DATE			SIGNED						
4. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (L	.MP) 15. C	DTHER DATE								
QUAL.	QUA	L.	MM DD	YY	FROM			TC		
7. NAME OF REFERRING PROVIDER OR OTHER SOURCE	17a.	NPI			18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES MM DD YY FROM TO 20. OUTSIDE LAB?					
i 9. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		Net .								
					YES	NO				
1. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate	A-L to servic	ce line below (24E	E) ICD Ind.		22. RESUBMIS	SION	ORI	GINAL R	EF. NO.	
B. [G47.31]	с. L G. L		D.		23. PRIOR AUT	HORIZATIC	N NUMBE	R		
· J	ы. Ц		H. L.		ABC987654	1321 *				
4. A. DATE(S) OF SERVICE B. C. I From To PLACE OF	(Explai	OURES, SERVICE		DIAGNOSI		D/	G. H. AYS EPSD DR Family NITS Plan	I. ID.	REND	J. DERING
IM DD YY MM DD YY SERVICE EMG	CPT/HCPC	CS	MODIFIER	POINTER	\$ CHARGE	S UÌ	OR Family VITS Plan	QUAL.	PROVI	DER ID. #
01 01 23 11	99214	25		A	XXXX	XX		NPI		
						104				
01 01 23 11	93151			A	XXXX	XX		NPI		
								NPI		
								NPI		
								NPI		
								1.000		
			07 40055			PCE	20 4440		ID 90 D	d for NUCC I
5. FEDERAL TAX I.D. NUMBER SSN EIN 26. PA	ATIENT'S A	CCOUNT NO.	27. ACCEF (For govt	T ASSIGNMENT? claims, see back)	28. TOTAL CHA	RGE	29. AMC		ID 30. Rsv	d for NUCC (

For questions or case management support, please call the **rem**edē Reimbursement Hotline at

1-952-540-4470 or email questions to reimbursement@remede.zoll.com.

- Costanzo M, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *The Lancet.* 2016; 388: 974–82.
- ² Costanzo MR, Khayat R, Ponikowski P, et al. State-of-the-art review: Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol 2015;65:72-84.
- ³ Costanzo MR, Javaheri S, Ponikowski P, et al. Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nat Sci Sleep. 2021;13:515-526.
- ⁴ Costanzo MR, Ponikowski P, Javaheri S, et al. Sustained Twelve Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. Am J Cardiol. 2018. pii: S0002-9149(18)30258-3. doi: 10.1016/j. amjcard.2018.02.022.
- ⁵ CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 70
- ⁶ ICD-10 PCS Expert for Hospitals, 2024.
- ⁷ CY 2025 MPFS CMS-1807-F, Addendum B. Payments calculated using Conversion Factor of \$32.3465.
- ⁸ ResMed and ZOLL Itamar Medical company website; accessed November 9, 2023.
- ° CMS-1809-FC; Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs. CY 2025 NFRM Addendum B.

Important Safety Information

The remedê^{*} System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. A doctor will need to evaluate the patient's condition to determine if the remedê System is appropriate. The remedê^{*} System should not be implanted during an active infection and patients will not be able to have diathermy (special heat therapies). The device is MR Conditional. The conditions and precautions can be found in the remedê System MRI guidelines manual. The remedê System may be used with another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The remedễ System as one to work for everyone. There are additional risks associated with removing the system. If it is decided to remove the system, another surgery will be required. Be sure to understand all the risks and benefits associated with the implantation of the remedễ System. For further information please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Contraindications**. The remedễ System is contraindicated for use in patients with an active infection. See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events.

Rx Only. The remedē* System, remedē* EL System, and remedē* EL-X System have received FDA approval. The remedē* System model 1001 has received CE Mark approval.

ZOLL Respicardia, Inc.

12400 Whitewater Dr., Suite 150 | Minnetonka, MN 55343 952-540-4470 | info@remede.zoll.com | remede.zoll.com



Copyright © 2024 ZOLL Medical Corporation. All rights reserved. Respicardia and **reme**dē are registered trademarks of ZOLL Respicardia, Inc. in the United States and/or other countries. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. RMB2579, Rev I